Financials in USD. Standardized financial statements.
A compact view of how Cosmo Pharmaceuticals N.V. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $104.82M | $266.79M | $92.78M | $102.09M | $65.07M | $60.95M | $62.49M | $65.62M | $67.24M | $67.66M |
| Revenue Growth? | -60.7% | +187.5% | -9.1% | +56.9% | +6.8% | -2.5% | -4.8% | -2.4% | -0.6% | 0.0% |
| Cost of Revenue? | $56.05M | $19.86M | $39.34M | $18.76M | $15.14M | $10.44M | $9.25M | $12.37M | $12.13M | $10.19M |
| Gross Profit? | $48.77M | $246.92M | $53.44M | $83.33M | $49.93M | $50.51M | $53.25M | $53.25M | $55.12M | $57.48M |
| Gross Margin? | +46.5% | +92.6% | +57.6% | +81.6% | +76.7% | +82.9% | +85.2% | +81.1% | +82.0% | +84.9% |
| Operating Expenses? | $59.25M | $98.04M | $47.29M | $55.27M | $21.00M | $26.43M | $65.56M | $69.87M | $64.72M | $32.08M |
| Operating Income? | -$10.48M | $148.88M | $6.15M | $28.06M | $11.10M | $6.91M | -$12.31M | -$16.62M | -$15.50M | $21.00M |
| EBITDA? | $2.36M | $165.71M | $19.70M | $46.74M | $17.81M | $7.84M | -$7.02M | -$12.33M | -$28.81M | $28.44M |
| Income Before Tax | -$923,719 | $153.37M | $1.53M | $24.47M | $24.00M | -$6.93M | -$21.30M | -$17.46M | -$32.43M | $27.49M |
| Income Tax Expense | $2.59M | $20.18M | $6.26M | $6.97M | $2.33M | $970,000 | $3.19M | $598,000 | $15,000 | $8.15M |
| Net Income? | -$3.63M | $133.24M | -$4.93M | $17.23M | $21.67M | -$7.90M | -$24.49M | -$18.06M | -$32.45M | $19.34M |
| EPS? | $-0.23 | $8.15 | $-0.31 | $1.05 | $1.29 | $-0.55 | $-1.67 | $-1.20 | $-2.19 | $1.37 |
| Diluted EPS? | $-0.23 | $8.12 | $-0.31 | $1.05 | $1.28 | $-0.55 | $-1.67 | $-1.20 | $-2.19 | $1.17 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality